Activation of NF-kappaB is involved in 6-hydroxydopamine-but not MPP+ -induced dopaminergic neuronal cell death: its potential role as a survival determinant

Biochemical and Biophysical Research Communications
Seong H ParkYoung J Oh

Abstract

The nuclear factor-kappaB (NF-kappaB) family plays an important role in the control of the apoptotic response. Its activation has been demonstrated in both neurons and glial cells in many neurological disorders. In the present study, we specifically examined whether and to what extent NF-kappaB activation is involved in culture models of Parkinson's disease following exposure of MN9D dopaminergic neuronal cells to 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-4-phenylpyridinium ion (MPP(+)). Both analysis by immunocytochemistry and of immunoblots revealed that NF-kappaB-p65 was translocated into the nuclei following 6-OHDA but not MPP(+)-treatment. A time-dependent activation of NF-kappaB induced by 6-OHDA but not MPP(+) was also demonstrated by an electrophoretic mobility shift assay. A competition assay indicated that not only NF-kappaB-p65 but also -p50 is involved in 6-OHDA-induced NF-kappaB activity. Co-treatment with an antioxidant, N-acetyl-l-cysteine, blocked 6-OHDA-induced activation of NF-kappaB signaling. In the presence of an NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), 6-OHDA-induced cell death was accelerated while PDTC did not affect MPP(+)-induced cell death. Our data may point to a drug-specific ...Continue Reading

References

Jan 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J E Bottenstein, G H Sato
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·H K ChoiA Heller
Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Jun 1, 1997·Trends in Neurosciences·L A O'Neill, C Kaltschmidt
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·S HunotE C Hirsch
Feb 13, 2001·The Journal of Clinical Investigation·M P Mattson, S Camandola
Jul 13, 2001·Biochemical Pharmacology·D BlumJ M Verna

❮ Previous
Next ❯

Citations

Apr 9, 2005·Neuropharmacology·Nevena RaicevicVladimir Trajkovic
Jan 7, 2006·Cell Death and Differentiation·M P Mattson, M K Meffert
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anamitra GhoshKalipada Pahan
Jan 18, 2007·Expert Opinion on Therapeutic Targets·Simonetta Camandola, Mark P Mattson
Sep 12, 2007·Journal of Neuroscience Research·Eva LinMichael J Zigmond
Sep 28, 2005·Neurochemical Research·Mark P Mattson
Feb 16, 2006·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jianxun Xie, Zahir A Shaikh
Nov 30, 2013·Journal of Neurochemistry·Ke WangWeihong Song
Nov 23, 2010·Reviews in the Neurosciences·Felicia Yu Hsuan Teng, Bor Luen Tang
Dec 13, 2018·Cell Death & Disease·Yuhyun ChungYoung J Oh
Nov 30, 2018·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Wei JinHong Qing
Aug 9, 2016·Medicina·Lolita KuršvietienėJurga Bernatonienė
Jan 3, 2020·Journal of Neural Transmission·Damir VarešlijaAndrew G McDonald
Sep 26, 2006·Biochemical Pharmacology·Sylvie Mémet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.